Literature DB >> 21219690

Serum procalcitonin in pulmonary tuberculosis.

T A Rasmussen1, O S Søgaard, C Camara, P L Andersen, C Wejse.   

Abstract

OBJECTIVE: To evaluate the level and prognostic value of procalcitonin (PCT) in a West African out-patient cohort with pulmonary tuberculosis (PTB).
METHOD: Patients were clinically scored (TB score), grouped into severity classes (SCs) upon diagnosis and followed for 12 months. Patients were categorised by comparisons of severity class (SC I+II or SC III) and levels of PCT and C-reactive protein (CRP) at diagnosis. Fifty healthy volunteers from the study area were used as controls. The association with TB score was explored using Spearman's rank correlation test. Survival curves stratified after baseline levels of PCT and CRP were compared using the log-rank test.
RESULTS: We included 218 patients in the study. PCT and CRP levels were low, but were significantly higher in patients than in controls (P < 0.001), and were higher for SC III compared to SC I+II patients (P = 0.021 for PCT, P < 0.001 for CRP). Human immunodeficiency virus (HIV) status did not influence results. We found positive correlations between both PCT and CRP and TB score. There was a significantly increased risk of mortality with increasing baseline PCT (P = 0.01), whereas high CRP did not predict mortality rate (P = 0.887).
CONCLUSION: In West African PTB patients, PCT levels were low but increased significantly with increasing severity of disease, and can predict mortality risk.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21219690

Source DB:  PubMed          Journal:  Int J Tuberc Lung Dis        ISSN: 1027-3719            Impact factor:   2.373


  8 in total

1.  Depressed Gamma Interferon Responses and Treatment Outcomes in Tuberculosis Patients: a Prospective Cohort Study.

Authors:  Jia-Yih Feng; Sheng-Wei Pan; Shiang-Fen Huang; Ying-Ying Chen; Yung-Yang Lin; Wei-Juin Su
Journal:  J Clin Microbiol       Date:  2018-09-25       Impact factor: 5.948

2.  Procalcitonin as a Diagnostic and Prognostic Factor for Tuberculosis Meningitis.

Authors:  Jinseung Kim; Si Eun Kim; Bong Soo Park; Kyong Jin Shin; Sam Yeol Ha; Jinse Park; Sung Eun Kim; Kang Min Park
Journal:  J Clin Neurol       Date:  2016-05-10       Impact factor: 3.077

Review 3.  Tuberculosis exposure, infection and disease in children: a systematic diagnostic approach.

Authors:  Claudia L Roya-Pabon; Carlos M Perez-Velez
Journal:  Pneumonia (Nathan)       Date:  2016-11-24

4.  The mask of acute bacterial pneumonia may disguise the face of tuberculosis.

Authors:  HamidReza Naderi; Fereshte Sheybani; Sedigheh Sadat Erfani; Bezat Amiri; Mehdi Jabbari Nooghabi
Journal:  Electron Physician       Date:  2017-03-25

5.  Interaction between host genes and Mycobacterium tuberculosis lineage can affect tuberculosis severity: Evidence for coevolution?

Authors:  Michael L McHenry; Jacquelaine Bartlett; Robert P Igo; Eddie M Wampande; Penelope Benchek; Harriet Mayanja-Kizza; Kyle Fluegge; Noemi B Hall; Sebastien Gagneux; Sarah A Tishkoff; Christian Wejse; Giorgio Sirugo; W Henry Boom; Moses Joloba; Scott M Williams; Catherine M Stein
Journal:  PLoS Genet       Date:  2020-04-30       Impact factor: 5.917

6.  The Sustained and Marked Elevation of Serum Procalcitonin in a Hemodialysis Patient with Tuberculous Lymphadenitis, but Without the Evidence of Sepsis: A Case Report.

Authors:  Peiyi Luo; Yanqiong Long; Liang Ma; Ye Tao; Shenju Gou
Journal:  Infect Drug Resist       Date:  2022-09-02       Impact factor: 4.177

7.  Risk factors related with mortality in patient with pulmonary tuberculosis.

Authors:  Chong Whan Kim; Sang-Ha Kim; Shun Nyung Lee; Seok Jeong Lee; Myoung Kyu Lee; Ji-Ho Lee; Kye Chul Shin; Suk Joong Yong; Won Yeon Lee
Journal:  Tuberc Respir Dis (Seoul)       Date:  2012-07-31

8.  Plasma Profiles of Inflammatory Markers Associated With Active Tuberculosis in Antiretroviral Therapy-Naive Human Immunodeficiency Virus-Positive Individuals.

Authors:  Oskar Olsson; Per Björkman; Marianne Jansson; Taye Tolera Balcha; Daba Mulleta; Habtamu Yeba; Christine Valfridsson; Fredric Carlsson; Sten Skogmar
Journal:  Open Forum Infect Dis       Date:  2019-01-31       Impact factor: 3.835

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.